XML 42 R26.htm IDEA: XBRL DOCUMENT v3.6.0.2
Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2016
Accounting Policies [Abstract]  
Schedule of Research and Development Expenses and Reimbursements
Information about the Company’s research and development expenses and reimbursements due under collaboration arrangements for the years ended December 31, 2016, 2015 and 2014 is presented as follows:
 
 
Years Ended December 31,
 
 
2016
 
2015
 
2014
Research and development expense, gross
 
$
20,706

 
$
17,380

 
$
8,717

Less: Reimbursement of research and development expense
 
630

 
940

 
430

Research and development expense, net of reimbursements
 
$
20,076

 
$
16,440

 
$
8,287
Summary of Antidilutive Securities Excluded from Computation of Weighted Average Common Stock Outstanding
The following potentially dilutive shares of common stock have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive
 
December 31,
 
2016
 
2015
Warrants to purchase Series C-1 Preferred
14,033

 
14,033

Warrants to purchase common stock associated with June 2016 Public Offering
4,218,750

 
—

Warrants to purchase common stock associated with Loan Agreement
122,435

 
—

Stock options
1,819,444

 
1,379,727
Schedule of Segment Reporting Information, by Segment
Information about the Company’s revenue, including revenue in continuing operations and discontinued operations, from different geographic regions for the years ended December 31, 2016, 2015, and 2014 is presented as follows:
 
Years Ended December 31,
 
2016
 
2015
 
2014
United States
$
—

 
—
%
 
$
6,931

 
90
%
 
$
16,422

 
86
%
Europe
—

 
—

 
477

 
7
%
 
1,235

 
7
%
Other non-US
257

 
100
%
 
257

 
3
%
 
1,367

 
7
%
Total revenue
257

 
100
%
 
7,665

 
100
%
 
19,024

 
100
%
Less: Revenue from discontinued operations
—

 
—

 
7,408

 
97
%
 
17,768

 
93
%
Revenue from continuing operations
$
257

 
100
%
 
$
257

 
3
%
 
$
1,256

 
7
%